Dual antiplatelet therapy in the contemporary drug-eluting stents era: from vulnerable stents to vulnerable patients

J Thromb Thrombolysis. 2022 Jul;54(1):153-155. doi: 10.1007/s11239-022-02639-z. Epub 2022 Mar 2.

Authors

Stefano Benenati¹, Italo Porto^{2

3}

Affiliations

¹ Cardiovascular Disease Chair, Department of Internal Medicine (Di.M.I.), University of Genoa, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy. stefanobenenatimd@gmail.com.
² Cardiovascular Disease Chair, Department of Internal Medicine (Di.M.I.), University of Genoa, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.
³ Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, IRCCS Italian Cardiology Network, Genova, Italy.

PMID: 35235123
DOI: 10.1007/s11239-022-02639-z

No abstract available

Keywords: Biodegradable polymer; Drug-eluting stent; Dual antiplatelet therapy; Durable polymer; Percutaneous coronary intervention.

Publication types

Editorial

MeSH terms

Absorbable Implants
Coronary Artery Disease* / therapy
Drug-Eluting Stents*
Everolimus
Humans
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors / therapeutic use
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Everolimus